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A B S T R A C T   
The objective was to evaluate the performance of decellularised porcine superflexor tendon (pSFT) as an anterior 
cruciate ligament (ACL) reconstruction device. The ACL of adult sheep was reconstructed with decellularised 
pSFT or ovine allograft SFT and animals sacrificed at 4, 12 and 26 weeks (n = 4 per group) for biological 
evaluation and 26 weeks (n = 6) for biomechanical evaluation of the grafts. Both grafts showed good in vivo 
performance with no major differences at macroscopic evaluation post euthanasia. Histopathology revealed an 
inflammatory reaction to both grafts at 4 weeks, which reduced by 26 weeks. There was advanced cellular 
ingrowth from 12 weeks, ligamentisation of intra-articular grafts, ossification and formation of Sharpey’s fibers 
at the graft/bone junctions. Immunohistochemistry showed that at 4 and 12 weeks, the host response was 
dominated by CD163+ M2 macrophages and a cell infiltrate comprising α-SMA + myofibroblasts, CD34+ and 
CD271+ progenitor cells. At 26 weeks the biomechanical properties of decellularised pSFT and oSFT grafts were 
comparable, with all grafts failing in the intra-articular region. This study provides new insight into constructive 
remodelling of tendons used for ACL replacement and evidence of integration and functional performance of a 
decellularised xenogeneic tendon with potential as an alternative for ACL reconstruction.   
1. Introduction 
Anterior cruciate ligament (ACL) tears are a common knee injury, 
particularly in the young and active population. Severe tears require 
replacement of the ligament to restore stability, with approximately 
7000 reconstructions per year in the UK [1] and over 100,000 in North 
America [2]. The aim of ACL surgery is to restore stability, enabling 
return to sport and activity, and to reduce the subsequent risk of 
arthritis. ACL reconstruction options include bone-patella tendon-bone 
or hamstring tendon autografts and allografts [3], all of which have 
limitations. The use of autograft tissue requires secondary surgery for 
the patient and carries the risk of morbidity at the donor site [4]. There 
is also the risk of an autograft having inadequate graft dimensions 
following harvest [5]. Allograft tissue avoids the problems of donor site 
morbidity and may allow ‘easier’ initial recovery, however the tissue 
remodelling process is slower compared to autografts [6] and inferior 
outcomes have been reported in young, highly active patients [6]. Al-
lografts derived from older donors have lower tensile strength and load 
to failure, hence the use of grafts from younger donors is preferable, 
especially for younger patients [6], and availability of suitable allografts 
may be a limitation [7]. Prosthetic ligaments are no longer recom-
mended for the reconstruction of the ACL, having a high rate of failure 
due to chronic inflammation and poor mechanical outcomes [8]. 
In response to these limitations, tissue-engineering approaches to 
ACL reconstruction are under investigation. Silk scaffolds formed 
through a variety of manufacturing methods have demonstrated prom-
ising results for ligament and ligament-bone healing in rabbit models of 
ACL repair [9,10]. Silk fibre scaffolds have also shown promising bio-
logical integration in a sheep model of ACL repair, although superior 
results were obtained in animals undergoing the addition of autologous 
stromal-vascular fraction to the scaffolds during implantation [11,12]. 
Although these studies are promising, more information is required on 
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the biomechanical performance of these grafts in large animal models to 
understand their full potential in ACL repair. Despite extensive 
pre-clinical research into methods of augmenting ACL reconstruction or 
biomimetic scaffolds for ACL replacement using stem cells or platelet 
rich plasma, these approaches have yet to reach the clinic [7]. The ideal 
solution would be regenerative, “off the shelf”, mechanically functional 
ACL reconstruction devices in a range of graft sizes matched to patient 
requirements. One promising approach to creating such regenerative 
devices for ACL reconstruction is to utilise decellularised xenogeneic 
ligamentous or tendon tissue. 
The process of decellularisation aims to remove the immunogenic 
cellular material from an animal or human donor tissue whilst main-
taining the extracellular matrix native ultrastructure, composition and 
biomechanical properties to create a biological scaffold. Upon implan-
tation, appropriately manufactured biological scaffolds can lead to 
constructive functional tissue remodelling and clinical success [13]. 
A range of biological scaffolds derived from human donor and animal 
tissues using different decellularisation processes are used extensively in 
surgical applications [13,14]. These are mainly derived from thin tissues 
such as human (eg Alloderm®, GraftJacket®) or bovine (eg Tissue-
Mend®) dermis, pericardium (eg. Veritas®) or porcine small intestinal 
submucosa (SIS, Surgisis®). Biological scaffolds have been evaluated for 
Achilles tendon reconstruction in mice (SIS [15]), rabbits (decellularised 
bovine tendon sheets [16]) and dogs (SIS [17]), and augmentation of 
rotator cuff repair in rats (decellularised human dermis [18]) and pri-
mates (decellularised porcine dermis [19]), with some evidence of 
constructive tissue remodelling. However, evidence suggests that tissue 
specific biological scaffolds which provide appropriate mechanical 
properties and induce appropriate cellular responses and constructive 
remodelling would be advantageous [14]. To date, there have been no 
reports of long term pre-clinical studies of homologous biological scaf-
folds for functional ACL replacement. 
We have developed decellularisation processes using low concen-
tration detergent (0.1% (w/v) sodium dodecyl sulphate; SDS) and pro-
teinase inhibitors for the production of tissue specific biological 
scaffolds which preserve the biomechanical and biological tissue prop-
erties. Processes have been developed for dermis [20], cardiovascular 
[21,22] and musculoskeletal [23] applications with evidence of suc-
cessful clinical translation [24,25]. The process has been adapted for a 
porcine superflexor tendon (pSFT) graft for ACL reconstruction [26]. 
This tendon has been shown to be mechanically superior to the native 
human ACL, even when irradiation is used as a terminal sterilisation 
method [27,28]. Decellularised pSFT grafts are typically 10–12 mm in 
diameter and demonstrate ultimate tensile strength (UTS) of 39.96 ±
3.68 MPa after sterilisation with 30 kGy gamma irradiation and 12 
months storage [27]. For the human ACL, UTS has been reported be-
tween 24.4 and 37.8 MPa [29,30], suggesting that these grafts can 
provide the appropriate mechanical properties for reconstruction. 
Moreover, the grafts can be stratified by size to provide varying me-
chanical properties [31]. There has been one study of the performance of 
pSFT grafts, reportedly decellularised using our approach, in sheep over 
12 weeks [32] which showed evidence of graft regeneration and func-
tional recovery, but with limited characterisation of the cellular 
response. The work has demonstrated the potential of the decellularised 
pSFT as an ‘off the shelf’ alternative to autograft or allograft tissues for 
ACL reconstruction. 
The primary objective of this study was to evaluate the biological 
integration of the decellularised pSFT as an ACL reconstruction device in 
the sheep knee over a six month period and to determine the biome-
chanical performance after 6 months implantation Secondary objectives 
were to (1) determine the cellular response to the implanted xenogeneic 
scaffold and determine whether the decellularised pSFT would be 
populated with endogenous cells over time using histology and a panel 
of antibodies to characterise the cell populations and (2) to compare the 
performance of the decellularised pSFT to a cellular ovine superflexor 
tendon allograft (oSFT). The sheep was chosen as the large animal 
species for this study because functional implantations of ACL re-
placements in sheep have been widely reported in the literature [33–37] 
and are recommended by international regulatory organisations for 
evaluation of ACL reconstruction devices [38]. Although smaller in size, 
the skeletally mature sheep knee is similar to the human knee in terms of 
anatomy, allowing anatomic graft fixation methods if smaller grafts are 
used [39]. 
2. Materials and methods 
Unless otherwise stated, all reagents used during the study were 
obtained from Sigma-Aldrich (Dorset, UK), VWR International (Lutter-
worth, UK) or Fisher Scientific (Leicestershire, UK). 
2.1. Procurement of porcine and ovine superflexor tendons 
The hind legs of female 70 kg, four month old, Large White pigs were 
obtained from an abattoir (J. Penny, Leeds) within 24 h of slaughter. The 
superflexor tendon (SFT) is located in the porcine foot running from the 
toe to the ankle. The porcine SFT (pSFT) was identified, isolated and 
cleaned of connective tissue following removal of the skin and subcu-
taneous tissue. Isolated SFTs were stored at − 80 ◦C on filter paper 
moistened with phosphate buffered saline (PBS; Oxoid) until required. 
The hindquarters of 1–2 year old female Texel sheep were obtained 
from an abattoir (M&C Meats, Crossgates, Leeds) within 6 h of slaughter. 
Ankle skin was cleaned and removed, and the subcutaneous tissue 
cleaned with Betadine® before aseptic dissection of the superflexor 
tendons. Ovine superflexor tendons (oSFT) were stored at − 80 ◦C. 
2.2. Decellularisation of pSFT 
Decellularisation of pSFT was carried out using a modified version of 
Jones et al. [26] using aseptic technique throughout. pSFT were thawed 
and split down the centre and the tendon halves were decellularised 
together to provide one sample for quality assurance (QA) and one for 
implantation. The tendons were split because it was deemed necessary 
following initial implantation trials, which revealed that a graft diam-
eter of 6–7 mm was required for the ovine knee. Tendons underwent a 
further dry freeze thaw, followed by two freeze/thaw steps in hypotonic 
buffer with aprotinin (10 mM tris, 2.7 mM EDTA, 10 KIU. ml− 1 aprotinin 
(Nordic Pharma), pH 8). Tendon halves were separated and washed 3 
times in acetone (50 ml) for 1 h each at 42 ◦C on an orbital shaker (240 
rpm; Grant, model PSU-10i) and then washed 5 times for 5 min with PBS 
supplemented with 10 KIU. ml− 1 aprotinin (PBS + A). The two paired 
tendon halves were placed in a 150 ml pot and sonicated for 15 min in 
100 ml PBS + A in an ultrasonicating water bath (VWR, model 
T20235X). The remaining treatments are detailed in Table 1; unless 
otherwise stated all steps were carried out with 100 ml of solution on an 
orbital shaker (240 rpm) and 10 min of sonication prior to any solution 
changes. 
Following the final PBS wash, tendons halves were separated and 
packaged aseptically in custom made foil/Tyvek pouches (Riverside 
Medical Packaging Ltd) and stored flat at − 80 ◦C until required for QA or 
shipping to NAMSA, Chass-sur-Rhone, France on dry ice for implanta-
tion in sheep. 
2.3. Quality assurance (QA) of tissues 
Decellularised split pSFT were assessed for sterility, removal of 
cellular material, maintenance of histological structure, total DNA 
content, biocompatibility and biomechanical properties. 
Sterility of oSFT was tested immediately following extraction using a 
small piece of tissue from both the toe and ankle regions. For decellu-
larised split pSFT, one half of the tendon was designated for QA and the 
other for potential use in the animal study. Sterility of pSFT was assessed 
following decellularisation and prior to packaging for every tendon 
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produced. This assessment was carried out by placing a small sample of 
the toe region of each QA tendon in 10 ml sterile nutrient broth (Oxoid), 
incubated at 37 ◦C for 48 h and checked for signs of cloudiness or film 
formation. Only tendons where the QA sample showed no signs of mi-
crobial growth were used in the animal study. For all other quality 
assurance analyses, tissue was taken from a set of 6 QA tendon halves, 
which were chosen at random from the packaged tissues. As the decel-
lularisation process had been previously established [26], it was deemed 
sufficient to perform checks to confirm decellularisation on a random 
subset of the tendons. 
2.4. Histological analysis 
Samples of decellularised pSFT from the ankle, middle and toe re-
gions of each of the 6 QA tendon halves were fixed in 10% (v/v) neutral 
buffered formalin (NBF) for 96 h, prior to paraffin wax-embedding using 
standard techniques. Serial sections (10 μm) were cut longitudinally 
with sections captured for staining every 200 μm for 1 mm. Sections 
from each level were stained with haematoxylin and eosin (H&E), DAPI 
and Masson’s trichrome as previously described [26]. All sections were 
viewed using an upright Carl Zeiss Axio Imager. M2 incorporating an 
Axio Cam MRc5, which was controlled by Zen Pro software 2012 (Zeiss). 
2.5. Determination of DNA content of native and decellularised pSFT 
Samples of the ankle-, mid- and toe-region of each of 6 native pSFT 
and the 6 QA tendon halves were finely macerated and mixed together. 
Triplicate samples (approx. 100 mg native; 250 mg decellularised) of the 
mixed-region tissue were lyophilized to constant weight. DNA was 
extracted from the lyophilized tissue using the DNeasy Blood & Tissue 
Kit (Qiagen) and the concentration of DNA in the extracts was deter-
mined by Nanodrop spectrophotometry at 260 nm. 
2.6. Determination of the biocompatibility of decellularised pSFT 
Contact cytotoxicity assays were used to evaluate the biocompati-
bility of the 6 QA tendon halves as previously described [26]. Murine 
L929 fibroblasts and Baby Hamster kidney (BHK) cells were cultured in 
contact with samples (approximately 2 × 2 × 5 mm) of tendon from each 
tissue region, which were attached to the bottom of six well plates using 
Steri-Strip™ (3 M). A drop of cyanoacrylate contact adhesive served as 
the positive control for cytotoxicity and Steri-Strip (3 M; 10 × 3 mm) as 
the negative control. Two plates were created for each tendon, con-
taining ankle, middle and toe regions of tissue, and cell only, positive 
and negative controls. The tissues and controls were incubated with 
L929 and BHK cells in an atmosphere of 5% (v/v) CO2 in air at 37 ◦C for 
48 h. Samples were viewed using phase contrast microscopy on an 
inverted microscope (Olympus UK, model IX71) and images of each 
sample were captured digitally. 
Cell monolayers were fixed in 10% (v/v) NBF for 10 min prior to 
staining with Giemsa stain. After rinsing off excess dye, samples were 
imaged again under bright field microscopy. The tissues were judged to 
be biocompatible if the cells grew up to and in contact with the edge of 
the samples. 
2.7. Tensile testing of decellularised porcine superflexor tendons 
Biomechanical properties of the QA tendon halves were obtained by 
simulating a trans-femoral fixation technique. The tendons were looped 
over a metal bar in a bespoke testing rig and sutured together at the 
opposite end (Fig. 1d). The lower end of the graft was fixed in place 
using a bespoke cryogrip filled with dry ice to prevent slippage during 
testing. 
Testing was carried out using an Instron 3365 (Instron, Bucks, UK) 
materials testing machine equipped with a 1000 N load cell. Twelve 
preconditioning cycles (15 mm min− 1, 0–50 N) were applied to the graft, 
followed by a ramp to failure at 30 mm min− 1. Stiffness, failure load and 
failure extension were determined from the load curves. Native pSFT 
were split as for decellularised tissues and the mechanical properties 
determined using the same method. 
2.8. In vivo performance of decellularised porcine superflexor tendons 
The in vivo study was conducted by the NAMSA test facility (Chasse- 
sur-Rhone, France) in adaptation of the ISO 10993 Standard on “Bio-
logical evaluation of medical devices”, Part 6 (2007). The study was in 
accordance with European requirements (2010/63EU) under a protocol 
approved by the NAMSA ethical committee (2015). NAMSA is an 
accredited facility registered with the French Department of Agriculture 
for animal housing, care and investigations. Prior to commencement of 
this study, implantation parameters were established through several 
pilot studies by the surgical and research team. Cadaveric sheep and 
sheep under non-recovery anaesthesia underwent graft implantation to 
establish the most appropriate combination of graft, tunnel and inter-
ference screw dimensions for the ovine knee. The ACL of 38 sheep (fe-
male, Blanche du Massif Central; 46–86 kg; 1.9–3.8 years) was then 
removed and reconstructed with split, decellularised pSFT (test) or 
cellular oSFT (allograft control). After 4, 12 and 26 weeks of implan-
tation, the behaviour of the implants and local tissue effects on the knee 
joint were macroscopically and histopathologically evaluated at 
NAMSA. After 26 weeks, the biomechanical performance of the pSFT 
and oSFT was evaluated at the University of Leeds. Details of the number 
of animals used for each group is presented in Table (2). The reserve 
Table 1 
Decellularisation process for porcine superflexor tendons following initial 
freeze/thaw cycles.  
Step Duration(s) Details 
1 Antibiotic wash solution (PBS 
containing 0.05 mg ml− 1 
vancomycin, 0.5 mg ml− 1 gentamicin 
and 0.2 mg ml− 1 Polymixin B) 
1 h 37 ◦C, agitation at 
80 rpm, no 
sonication 
2 Hypotonic buffer (10 mM tris, 2.7 
mM EDTA) pH 8.0 with aprotinin (10 
KIU.ml− 1) 
66–72 h 4 ◦C 
3 Hypotonic buffer with SDS (10 mM 
tris, 2.7 mM EDTA, 0.1% (w/v) SDS) 




4 Hypotonic buffer, as Step 2 22–24 h; 
two washes 
4 ◦C then 42 ◦C 
5 Hypotonic buffer with SDS (0.1% w/ 
v), as Step 3 
66–72 h 42 ◦C 
6 Hypotonic buffer, as Step 2 22–24 h; 
two washes 
4 ◦C then 42 ◦C 
7 Hypotonic buffer with SDS (0.1% w/ 




8 PBS (Oxoid) supplemented with 10 






9 Nuclease treatment (50 mM tris, 
1 mM MgCl2⋅6H20, 10 U.ml-1 




37 ◦C, agitation at 
80 rpm, no 
sonication 
10 PBS 22–24 h 42 ◦C 
11 Hypertonic (50 mM tris, 1.5 M 
sodium chloride, pH 7.6) 
22–24 h 42 ◦C 
12 PBS 66–72 h 42 ◦C 
13 Peracetic acid (PAA; 0.1% v/v 
peracetic acid in PBS, pH 6) 
3 h 27 ◦C 
14 PBS 30 min; 3 
washes 
42 ◦C, no sonication 
15 PBS 22–24 h; 4 
washes 
Alternated 42 ◦C and 
4 ◦C 
16 PBS 66–72 h 42 ◦C 
17 PBS 22–24 h; 4 
washes 
Alternated 42 ◦C and 
4 ◦C 
18 PBS 66–72 h 42 ◦C  
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sheep were operated upon using the same surgical procedure as the 
other sheep in case of adverse events and then followed in the same 
manner up to the end of the study. The number of animals in each group 
was the minimum required to evaluate the biological integration and 
biomechanical performance at 6 months based upon the literature 
[33–37]. 
2.9. Surgical procedure and animal husbandry 
Prior to surgery, pSFT and oSFT grafts were thawed in their pack-
aging and transferred to sterile saline soaked gauze in the operating 
theatre. Grafts were trimmed to 11 cm length, 7 mm diameter and a 
passing suture (Ethibond® 1 or Ethibond® 2) placed at each end along 
Fig. 1. Implantation schematic and quality assurance of decellularised pSFT for implantation. A schematic of graft placement is provided for reference (a). 
Biological characterisation shows representative images (b) following staining of histological sections of native (top row) and decellularised (bottom row) tissues 
with H&E, DAPI and Masson’s trichrome. The same exposure settings were used for DAPI images of fresh and decellularised pSFT. In vitro contact cytotoxicity testing 
(c) of decellularised pSFT using BHK (top row) and L929 (bottom row) cell lines. Representative images shown of pSFT samples, cell only wells and cyanoacrylate 
positive controls; scale bars show 200 μm. Biomechanical testing setup (d) demonstrates the sutured, split tendon, bespoke fixture rig and system clamped in place on 
the testing machine, as well as the stiffness, load at failure and extension at failure of native and decellularised tendons. Graphs show mean ± 95% confidence 
intervals. * denotes significant difference between groups (p < 0.05, upaired t-test). 
Table 2 
Details of the number of animals used during the study for clinical, histological and biomechanical analysis.  
Time period Number of animals Macroscopic and histopathologic analysis Macroscopic and biomechanical analysis Clinical observations 
pSFT oSFT pSFT oSFT Contralateral knees pSFT oSFT 
4 weeks 8 4 4 0 0 0 18 18 
12 weeks 8 4 4 0 0 0 14 14 
26 weeks 20 4 4 6 6 6 10 10 
Reserves 2 / / 1 1 / 1 1  
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for approximately 10–15 mm. 
Sheep were weighed and premedicated (intravenous; IV) with diaz-
epam (Valium®, Roche) and butorphanol (Torbugesic®, Pfizer or Tor-
phasol®, Axience) and anaesthetised (IV) using propofol (Propovet®, 
Abbot). Sheep were intubated and mechanically ventilated. Anaesthesia 
was maintained by inhalation of oxygen-isoflurane (Iso-Flo®, Axience). 
Pre-operatively sheep received an intramuscular (IM) injection of a non- 
steroidal anti-inflammatory (flunixine, Meflosul®, Zoetis) and peri- 
operatively an antibiotic (IM; amoxicillin, Duphamox®, LA). Sheep 
were placed in dorsal recumbency and monitored throughout the pro-
cedure. Surgeries were performed by a veterinary surgeon. The joint was 
opened by a lateral arthrotomy and the ACL removed. The knee was then 
moved in the sagittal plane to verify the anterior laxity between the 
femur and tibia (drawer test). A tibial guide rail (Mitek) was hooked into 
the ACL tibial insertion and the angle was set at approximately 50–55◦. 
A crossing tibial tunnel was drilled from the medial/proximal tibia to the 
tibial plateau, then over-drilled with an acorn reamer (Mitek) to a final 
diameter of 7 mm. The extra-articular and intra-articular edges of the 
tibial tunnel were softened with a 7 mm dilatator to prevent wear on the 
graft. The femoral tunnel was similarly prepared (angle 40–45◦, tunnel 
diameter 8 mm). The passing suture placed on the test or control grafts 
was introduced through the tibial and femoral tunnels using a pin with 
an eyelet. The extra-articular edge of the femoral tunnel with the article 
was enlarged with a 7 mm dilator (approximately 10 mm deep) and a 
bioresorbable interference screw (Milagro BR, Mitek; 7 mm ø, 23 mm 
long) was manually inserted into the tunnel using a modular driver. The 
extra-articular edge of the tibial tunnel with the graft enlarged and the 
graft firmly held with a tie tensioner (5 lb) using the two passing sutures 
while the knee was maintained in a half-flexion position. An interference 
screw (Milagro BR, Mitek; 7 mm ø, 30 mm long) was then manually 
inserted in the tibial tunnel using a modular driver. Grafts were cut at 
the tunnel’s exit and no passing suture remained in the bone tunnels. A 
schematic of the placement of the graft within tunnels is shown in 
Fig. 1a. 
The tension of the articles was checked in hyperflexion and hyper-
extension before movement of the knee in the sagittal plane to verify the 
absence of laxity after ACL reconstruction. The joint capsule and the 
muscles were separately closed using discontinuous (simple interrupted) 
absorbable sutures (1 PDS™ II, Ethicon). The subcutaneous layer was 
closed using absorbable continuous suture (Vicryl® 2.0, Ethicon) and 
the skin using surgical staples (Covidien™). The surgical wound was 
disinfected with iodine solution (Vetedine® solution, Vetoquinol). 
The sheep were kept in a sling for approximately 24 h after the 
surgery to minimize the risk of traumatic movement during the recovery 
from anaesthesia. While in the sling, the operated legs were moved at 
their full amplitude three to five times a day. After this period, the sheep 
were housed without restriction of movement (stifles loaded) individ-
ually or in a group in a limited space but always keeping social contact, 
under standardised laboratory conditions. Food and water were pro-
vided ad libitum. The operated legs were moved at their full amplitude 
once to twice a day during the first two weeks of the study. Buprenor-
phine was administered once to twice daily for 6 days post-surgery and 
flunixine (Meflosyl®, Pfizer) daily for 10 days. Every two days for 14 
days, amoxicillin (Duphamox LA®, Pfizer) was administered and 
wounds disinfected with iodine solution (Vetedine® solution, Vetoqui-
nol). Surgical staples were removed after complete healing (14 days 
after surgery). 
2.10. Clinical follow-up 
The sheep were observed daily. The gait (including assessment of 
flexion and extension through manual manipulation and observation of 
animals during walking on a flat surface), weight bearing, swelling of 
the site, stiffness of the leg and cracking at flexion was evaluated once a 
week during the first month and then every month until the end of the 
study. At 4, 12 or 26 weeks following surgery the designated sheep were 
weighed and euthanised by IV injection of pentobarbital. Qualitative 
macroscopic observations of the synovial fluid, graft and knee joint 
tissues were made at necropsy and images of the operated knee were 
captured. If an animal became injured, ill or moribund during the course 
of the study, care was conducted in accordance with current veterinary 
medical practices. When warranted for humane reasons, euthanasia was 
conducted following veterinary advice, a full necropsy was conducted to 
determine the cause of death and implanted sites were sampled and 
fixed in 10% (v/v) neutral buffered formalin for further histopathologic 
evaluation. 
2.11. Cytological analysis of the synovial fluids 
After smearing, the synovial fluids (n = 4 per group and time point) 
sampled at termination were stained with May-Grunwald Giemsa and a 
qualitative and semi-quantitative evaluation of the cellular components 
(monocytes, polymorphonuclear cells (PMNs), lymphocytes, synovio-
cytes) plus the presence of particulates was carried out. Cells were 
graded from 0 (absent); 1 (slight or 1–5 cells per field of view at 400×
magnification), 2 moderate (or 6–10 cells per FoV), 3 (marked or heavy 
cell infiltrate) and 4 (severe or packed cells). 
2.12. Histopathological evaluation of local tissue effects and integration 
After 4, 12 or 26 weeks, sheep with ACL reconstructions comprising 
oSFT and pSFT (n = 4 per group) were sacrificed for macroscopic and 
histopathological evaluation of the grafts and surrounding tissues. 
Following euthanasia, mobility of the joint was assessed (drawer test, 
joint stiffness, swelling) prior to dissection of the joint. Extracapsular 
tissues were removed to allow visualisation of the graft and macroscopic 
evaluation was carried out to assess adverse effects on the joint. For 
histological analysis of the intra-articular graft, the central third of each 
oSFT and pSFT graft was extracted and fixed in 10% (v/v) NBF, prior to 
dehydration and embedding (longitudinal and transverse samples) in 
paraffin wax. Sections were cut and stained with safranin-haematoxylin- 
eosin (SHE). The two remaining pieces of graft within the joint space 
were snap frozen in liquid nitrogen and stored at − 40 ◦C. Samples of the 
posterior cruciate ligament (PCL), meniscus, popliteal lymph node, sy-
novial membrane and smears from synovial fluid of the operated knee 
were also collected and processed for histological evaluation. For his-
tological evaluation of tissue integration in bone tunnels, femoral and 
tibial insertion sites were excised and fixed in 10% (v/v) NBF prior to 
dehydration and embedding in poly(methyl methacrylate) (PMMA). 
One longitudinal section of each was produced using an Exakt 
(Hamburg-Norderstedt, Germany) grinding system and stained with 
modified Paragon. 
Histological sections were assessed for cellular infiltration, cell type, 
tissue remodelling and integration by a trained pathologist at NAMSA. A 
qualitative and semi-quantitative histopathologic evaluation of the local 
tissue effects was conducted based on an adaptation of ISO10993, 
“Biological evaluation of medical devices” Part 6 (2007). Sections of the 
graft tissue were graded from 0 (absent); 1 (slight or 1–5 cells per field of 
view at 400× magnification), 2 moderate (or 6–10 cells per FoV), 3 
(marked or heavy cell infiltrate) and 4 (severe or packed cells) for PMNs, 
lymphocytes, plasma cells, macrophages and giant cells/osteoclastic 
cells and performance parameters. For sections of the bone tunnels, 
performance parameters were assessed using the same grading system 
with analysis of the presence of Sharpey’s fibres, quality of the tendon- 
bone junction in the bone tunnels, osseointegration (between the 
interference screw and the native femoral/tibial bone), neo-
vascularization and screw degradation. 
2.13. Histological and immunohistochemical analysis of graft tissue 
Remaining NBF fixed paraffin embedded tissue blocks and snap 
frozen tissue samples were returned to the University of Leeds for further 
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assessment of the cellularity of the central regions of the graft tissue 
only. The tissue was thawed and fixed using zinc fixative (0.1 M tris; 3.2 
mM calcium acetate [Thermo Fisher scientific], 27 mM zinc acetate 
[Sigma Aldrich], 37 mM zinc chloride [Fluka]; pH 7.2) for 48 h. The zinc 
fixed samples were processed automatically (Leica 11,020 tissue pro-
cessor) and embedded in paraffin wax. For comparative purposes, native 
ovine ACL tissue sections were evaluated using four ovine ACLs from 
Blanche du Massif Central sheep aged 20 months (NAMSA) from animals 
which were euthanised as part of other studies not relating to muscu-
loskeletal conditions. 
Routine histological staining techniques (haematoxylin & eosin 
(H&E), DAPI, Masson’s trichrome) were applied to NBF-fixed fixed tis-
sue sections (12 μm). Sections (12 μm) of NBF and zinc fixed tissues were 
taken and labelled using a range of antibodies as detailed in Table 3. The 
Dako EnVision Detection System, Peroxidase/DAB (Agilent Technolo-
gies) was used for antibody detection. The primary antibodies, dilutions, 
method of antigen retrieval and positive control tissues were established 
in extensive preliminary studies. Isotype control antibodies (Dako, 
Agilent Technologies) and omission of the primary antibodies were used 
to verify antibody specificity and as negative controls. Images were 
captured using an upright Carl Zeiss Axio Imager. M2 incorporating an 
Axio Cam MRc5, which was controlled by Zen Pro software 2012 (Zeiss). 
Sections were subject to semi-quantitative analysis. For cell markers 
the number of positive cells per high power field of view (FoV; 40×
objective; 400× magnification) were counted and scored 0 for no cells; 1 
(rare) for 1–5 cells; 2 (moderate) for 6–10 cells; 3 (marked) for a heavy 
infiltrate and 4 (packed) for packed cells. For matrix proteins (tenascin C 
and collagen III) sections were scored 0 (absent), 1 (slight), 2 (moder-
ate), 3 (strong) and 4 (intense). 
2.14. Biomechanical performance 
Biomechanical testing of ovine knees was carried out 26 weeks 
following ACL reconstruction. Whole knees were excised and frozen 
following euthanasia and shipped to Leeds on dry ice. Prior to testing, 
knees were thawed and the ends of the femur and tibia potted in PMMA 
cement and stored at 4 ◦C overnight. All remaining excess tissue, 
including musculature, extracapsular ligaments and menisci was 
dissected from the joint and the lateral condyle removed. Knees were 
secured in an Instron 3365, the PCL cut before alignment of the graft and 
bone tunnels to the axis of loading, providing a worst-case loading 
scenario. Samples underwent ten preconditioning cycles (100 mm s− 1, 
0–20 N) prior to testing to failure (200 mm s− 1). In addition to testing of 
pSFT and oSFT grafts following 26 weeks implantation, native ovine 
ACLs (contralateral knees from sheep used in the study; n = 6) were 
tested using the same loading protocol. To investigate whether the 
biomechanical performance improved by 26 weeks compared to 
immediately following implantation, split pSFT not used in the study 
were implanted into the cadaveric contralateral knees (pSFT(C); n = 6). 
These implantations were carried out using the same surgical tools and 
procedures and underwent biomechanical testing using the same 
loading protocol as all other groups. 
2.15. Statistical analysis 
Scores for semi-quantitative analysis of the cellularity of the grafts 
are expressed as mean (n = 4) ± SD. One-way ANOVA was used to 
compare biomechanical properties of native ACLs, decellularised pSFT 
in cadaveric knees (pSFT(C)) and oSFT and decellularised pSFT 26 
weeks post implantation. Tukey’s post-hoc analysis was used to assess 
the significance of differences between groups (p < 0.05). 
3. Results 
3.1. Quality assurance of decellularised tendons 
None of the tendons tested showed any signs of microbial contami-
nation. Observations of tissue sections stained with H&E demonstrated 
that the histoarchitecture of the pSFT had been maintained during 
decellularisation and there was no evidence of cells or cell nuclei 
remaining (Fig. 1b). DAPI stained tissue sections showed no evidence of 
whole nuclei or DNA, with the exception of some small fragments in 
Table 3 
Details of antibodies used for immunohistochemical labelling of tissue sections. Isotype and reagent controls were included for all test groups, as well as positive 
control ovine tissue sections. For tissues fixed with zinc fixative, no antigen retrieval methods were used. ‘Incubation’ column refers to the primary antibody incubation 
step. RT: room temperature. * Sections blocked for 30 min using 2% (v/v) milk in TBS immediately prior to application of primary antibody.  
Antigen Supplier Product code Working 
dilution 
Isotype Antigen retrieval Incubation Positive 
control 
Antigen relevance 
CD3 Leica NCL-L-CD3- 
565 
1:125 IgG1 N/A (zinc) RT, 30 min Sheep thymus Pan T-cell marker 
CD19 Leica NCL-L-CD19- 
163 
1:50 IgG2b N/A (zinc) RT, 60 min Sheep lymph 
node 
Pan B-cell marker 
CD163 AbD 
Serotec 
MCA1853 1:100 IgG1 Protease K (Dako 
Agilent), RT, 20 min 
RT, 45 min Sheep lymph 
node 
Heamoglobin/haptoglobin scavenger receptor 
Macrophages/M2 macrophages [40–44] 
CD80 AbD 
Serotec 
MCA2436GA 1:25 IgG1 Protease K, RT, 
20 min 
RT, 45 min Sheep lymph 
node 




MCA874GA 1:100 IgG1 Protease K, RT, 
20 min 
RT, 2 h Sheep lymph 
node 
Recently infiltrating macrophages [MRP 14] 
and PMNs [48–50] 
α-SMA Dako M0851 1:100 IgG2a Protease K, RT, 
20 min 
RT 60 min Sheep 
pulmonary 
artery 
Myofibroblast marker, observed during wound 
healing [51,52] 
CD271 Biolegend 345,102 1:100 IgG1 Protease K, RT, 
20 min 
RT 60 min Sheep aorta LNGFR (Low affinity nerve growth factor) 
multipotent stromal cells [53] 
CTGF Abcam Ab6992 1:100 IgG1 Protease K, RT, 20 
min + Trypsin-EDTA 
(Sigma), 30 s 
RT, 30 min Sheep skin Connective tissue growth factor; roles in cell 
adhesion, migration, proliferation, 
angiogenesis, tissue wound repair and fibrosis 
[54,55] 
CD34 Abcam Ab81289 1:500 Rabbit 
IgG 
N/A (zinc) 37 ◦C, 1 h* Sheep skin Surface glycoprotein heamatopoietic stem 
cells; diverse progenitors [56,57] 
Col III Abcam Ab7778 1:1000 Rabbit 
IgG 




Abcam Ab3970 1:50 IgG1 N/A (zinc) 4 ◦C, 
overnight* 
Sheep tonsil Expressed in healing tendons and bone [60,61] 




Marker of cell proliferation  
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endotendon regions (Fig. 1b). These results were consistent across the 
ankle-, middle- and toe regions of the grafts. Masson’s trichrome stained 
tissue sections showed an absence of cytoplasmic material in the bulk of 
the tissues (Fig. 1b), with any fragments remaining contained in single 
patches of endotendon. 
Biocompatibility testing showed no evidence of in vitro cytotoxicity 
from any region of any decellularised pSFT (Fig. 1c). Both BHK and 
L929 cells grew up to the edge of the tissue sections, with no observable 
differences in morphology compared to cells alone and no signs of the 
voids present around cyanoacrylate controls. 
Fresh pSFT had a total DNA content of 785.5 ± 112.2 ng mg− 1 (mean 
n = 6 ± 95% confidence limits) dry weight tissue. In decellularised 
tendons, this was reduced to 14.9 ± 7.1 ng mg− 1 (mean n = 6) an 
average reduction of 98.1%. 
There was no significant difference in the stiffness of split native 
pSFT compared with split decellularised pSFT (223.2 ± 24.3 N mm− 1 vs 
226.4 ± 21.0 N mm− 1 respectively [mean n = 6 ± 95% confidence 
limits]; 6–7 mm diameter grafts; Fig. 1d; top graph). There was a sig-
nificant (p < 0.05) reduction in the load at failure (1528 ± 173 N native 
vs 1238 ± 156 N decellularised; Fig. 1d; middle graph) and an increase 
in extension at failure (10.78 ± 0.48 mm native vs 13.42 ± 1.59 mm 
decellularised; Fig. 1d; bottom graph). 
3.2. Post-operative clinical observations 
On day 1, one sheep was found dead due to compression of the tra-
chea by the whole body sling used to prevent weight bearing during the 
first 24 h. Following this incident, slings were modified to prevent any 
other animals becoming tangled in the supports. Two sheep of the 4 
week time period (one oSFT and one pSFT) slightly lost weight (2 and 
3% respectively), which was associated with absent to slight weight 
bearing for one sheep. All sheep gained weight between implantation 
and termination. One sheep was euthanised on day 6 due to continued 
lack of standing over two days. Traumatic injury; likely due to sheep in 
the same pen, was confirmed at necropsy. 
Some minor abnormalities were observed during the follow-up at a 
distance from the implanted sites that were not considered to have 
impacted the study results. One sheep in the oSFT group showed delayed 
wound healing to day 72. The wound was treated but affected follow-up 
on this sheep. At termination (26 weeks), synovial fluid was slightly pink 
but the abnormality was not considered to have impacted the study 
results. 
No abnormalities, other than those features frequently found 
following ligamentoplasty were observed during the clinical follow-up. 
No major differences were observed in weight bearing, gait, joint 
alignment, swelling or cracking at flexion between sheep implanted with 
oSFT and decellularised pSFT at any time point. The number of sheep 
displaying abnormalities in these at each time point is summarised in 
Table 4. The gait of the sheep was observed to be normal or almost 
normal from one week after the surgery. 
3.3. Macroscopic observations at termination 
At termination, post-operative complications such as knee swelling 
Table 4 
Occurrence of macroscopic observations at termination. Figures indicate number of sheep demonstrating parameter at observation with the exception of the 
Outerbridge classification which was scored as follows: 0 = normal cartilage; 1 = cartilage softening and swelling; 2 = Partial-thickness defect with fissures on the 
surface that do not reach subchondral bone or exceed 1.5 cm in diameter; 3 = Fissuring to the level of subchondral bone in an area with a diameter more than 1.5 cm; 4 
= Exposed subchondral bone.  
Parameters observed for sheep dedicated for 
histopathology and biomechanical analysis 














Decell pSFT* (n =
11) 
Synovial fluid Abnormal colour 1 4 1 1 3 3 
Abnormal clearness 1 3 3 3 3 3 
Abnormal viscosity 4 4 1 1 0 2 
Effusion (marked amount) 1 1 1 0 0 1 
Graft Taut in flexion and extension 0 0 3 1 3 2 
Taut in flexion and not 
visible in extension 
0 0 0 0 2 2 
Slacked in extension (taut in 
flexion) 
3 2 0 1 4 6 
Slacked in flexion and 
extension 
1 2 1 2 2 1 
Broken 0 0 0 0 0 0 
Ravelling/signs of damage 3 2 2 1 1 0 
Gait Limping 1 2 1 1 1 3 
Movement of the knee Cracking 1 3 2 2 7 8 
Knee Swelling 3 3 3 2 0 0 
Antero-posterior laxity 1 0 1 0 1 0 
Parameters observed for sheep dedicated for 
histopathology 
/ / / / Ovine 
SFT* (n = 4) 
Decell pSFT* (n = 4) 
Synovial membrane Discoloration/red spots 2 4 3 0 0 0 
Menisci Tear 0 0 1 0 0 0 
Superficial tears 1 0 0 0 0 0 
Displacement 0 0 0 0 1 0 
Patella Erosion 0 0 0 0 1 0 
Outerbridge scores 0; 0; 0; 0 1; 0; 0; 0 0; 0; 0; 0 0; 0; 0; 0 0; 0; 2; 0 0; 0; 0; 0 





1; 1; 1; 0 
1; 2; 2; 2 
1; 1; 1; 0 
2; 1; 2; 1 
1; 0; 1; 1 
1; 0; 1; 2 
2; 1; 1; 1 
0; 2; 1; 1 
1; 1; 3; 0 
2; 2; 3; 1 
1; 1; 2; 0 
2; 2; 1; 2 





0; 0; 0; 0 
1; 2; 0; 0 
0; 0; 0; 0 
1; 0; 1; 0 
0; 1; 0; 0 
1; 1; 2; 1 
0; 0; 1; 0 
0; 2; 1; 0 
0; 1; 2; 0 
1; 1; 1; 1 
0; 0; 2; 0 
2; 1; 2; 0 
Posterior cruciate 
ligament 
Separated fibers 0 0 1 0 0 0  
J.H. Edwards et al.                                                                                                                                                                                                                             
Biomaterials 279 (2021) 121204
8
(only at 4 and 12 weeks), chondral erosion and graft slack occurred at 
similar incidences in both the decellularised pSFT and oSFT group 
(Table 4). Images of the macroscopic joint features at 26 weeks are 
provided in Fig. 2. Full details of the macroscopic observations at 
termination, together with images of each joint are openly available 
from the University of Leeds Data Repository [62]. 
3.4. Cytological evaluation of synovial fluids 
The results of cytological evaluation of synovial smears are presented 
in Table (5). At 4 weeks, synovial smears from two sheep implanted with 
a pSFT and one from a sheep implanted with an oSFT suggested an intra- 
articular inflammatory process with moderate cellularity and presence 
of PMNs. The presence of infection could not be excluded. No significant 
cellular response was noted for any of the other synovial fluids. At 12 
weeks, one synovial smear from a sheep implanted with an oSFT sug-
gested an intra-articular inflammatory process with presence of a 
mixture of synoviocytes, PMNs, lymphocytes and monocytes. No sig-
nificant cellular response was observed in the three other synovial fluids 
from sheep implanted with oSFTs. For the synovial fluids from sheep 
implanted with pSFT, all synovial smears were considered to be within 
normal limits. At 26 weeks, the level of inflammation observed in the 
synovial fluids was considered to be adverse only in one sheep 
implanted with a pSFT which showed an intra-articular inflammatory 
process with lymphocytes and PMNs and an infectious origin could not 
be excluded. There was no material suggestive of article residues or 
debris in any of the smears at any time point. 
3.5. Histolopathological evaluation of local tissue effects and integration 
The complete pathology report including the semi-quantitative 
analysis of each graft tissue, synovial membrane, menisci, PCL, popli-
teal lymph nodes and synovial is openly available in the University of 
Leeds Data Repository [62]. A summary of the semi-quantitative 
histopathologic analysis of the femoral bone tunnels and intra-articular 
grafts is presented in Tables (6) and (7) respectively. The analysis of the 
tibial bone tunnels was similar to the femoral bone tunnels (data not 
shown). 
Representative images of cellular infiltration in the intra-articular 
grafts and integration of the grafts within the bone tunnels are pre-
sented in Figure (3). After 4 weeks, the two decellularised pSFT and one 
oSFT showing moderate to marked cellularity in synovial smears also 
had moderate to marked signs of inflammation in the intra-osseus and 
intra-articular parts of the graft (Table 6; Table 7). Overall, at 4 weeks, 
histopathological analysis indicated an ongoing inflammatory response 
in the bone tunnels (Table 6) and grafts (Table 7) comprising PMNs, 
lymphocytes, plasma cells and macrophages with some evidence of 
slight necrosis. Nevertheless, both the decellularised pSFT and oSFT 
showed evidence of peripheral cellular ingrowth in the intra-articular 
part of the graft and intra-osseous sites (Fig. 3; Table 6). The interface 
between the graft and the bone showed very slight signs of calcification 
and ossification, with moderate signs of osseointegration of the inter-
ference screw (Table 6). Overall, there were no relevant differences 
between the two groups. 
After 12 weeks, the overall severity of the local tissue effects was 
decreased and performance parameters increased for both groups when 
compared with the 4 week results. Both the decellularised pSFT and 
oSFT showed evidence of marked cellular ingrowth in the intra-articular 
graft and within the bone tunnels (Fig. 3; Tables 6 and 7). Moderate to 
marked ligamentisation was evident in the intra-articular graft sections 
(Fig. 3; Table 7). The interface between the graft and the bone showed 
slight to moderate signs of calcification and ossification, formation of 
Sharpey’s fibers, and ACL/bone junctions of moderate quality (Table 6). 
When compared with the oSFT group, decellularised pSFTs had slightly 
higher mean scores of inflammatory cells but slightly higher mean scores 
of ligamentisation in both the intra-articular (Table 7) and intra-osseous 
parts of the grafts (Table 6). In view of the small size of the groups, these 
slight differences were not considered to be quantitatively relevant. 
Fig. 2. Macroscopic images of tibial and femoral cartilage surfaces 26 weeks post implantation. No difference in the prevalence of damage or lesions was 
observed between oSFT and pSFT groups. Images taken from ovine knee joints dissected for biological analysis. 
J.H. Edwards et al.                                                                                                                                                                                                                             
Biomaterials 279 (2021) 121204
9
After 26 weeks, there were no major changes in local tissue effects 
and performance parameters when compared with the 12-week period. 
The decellularised pSFT had slightly higher mean scores of inflamma-
tory cells compared with oSFT, however, infection could not ruled out 
for one of these grafts. This did not appear to impact on the graft per-
formance, which was similar for both groups. 
3.6. Histological and immunohistochemical analysis of intra-articular 
graft and native ovine ACL tissues 
Sections of native ovine ACLs and grafts explanted at each time-point 
were stained with H&E, DAPI and Masson’s trichrome to evaluate the 
cellularity and overall tissue structure. Representative images of sec-
tions stained with DAPI and Masson’s (H&E not shown) are presented in 
Figure (4). Analysis of these tissue sections supported the histopatho-
logical observations of extent of inflammation, cellular ingrowth, vas-
cularisation and ligamentisation of both the decellularised pSFT and 
oSFT tissues over time, which was similar for both groups. Data on the 
semi-quantitative evaluation of the immunohistochemical analysis of 
the matrix and cells populating the native ovine ACL and explanted 
tissues are presented in Figure (5) and representative images presented 
in Figures (6) and (7). 
The majority of the stromal cells in sections of native ovine ACL 
stained weakly positive for α-SMA (Figs. 5a and 6a). Strongly stained 
α-SMA + cells were present in the walls of the vascular structures and 
the vascular endothelium stained positive with antibodies to CD34 
(Fig. 6b). A variable proportion of the elongated stromal cells along the 
collagen fibres stained positive for CD34 (Fig. 6b). CD271+ cells were 
specifically located surrounding vascular structures, presumably repre-
senting pericytes (Fig. 6c). The extracellular matrix of the ovine ACLs 
was negative for tenascin-C (Figs. 5d and 6d). There was mild, but clear 
staining of the ligament collagen fibrils with antibodies to collagen III 
(Figs. 5e and 6e). There were no CD3+ (Figs. 5f and 7a), Ki-67+ (Figs. 5g 
and 7b), CD19+ or CD80+ (data not shown) cells in the native ACL 
Table 5 
Summary of the semi-quantitative histopathologic evaluation of the synovial fluids. After smearing, the synovial fluids (n = 4 per group and time period) 
sampled at termination were stained with May-Grünwald Giemsa (MGG). A qualitative and semi-quantitative evaluation of the cellular components (monocytes, 
PMNs, lymphocytes, synoviocytes) was conducted and graded from 0 (absent); 1 (slight or 1–5 cells per field of view at 400× magnification), 2 moderate (or 6–10 cells 
per FoV), 3 (marked or heavy cell infiltrate) and 4 (severe or packed cells). * The possibility of infection could not be ruled out for the explants from three sheep at 4 
weeks (two decellularised pSFT and one ovine SFT) and from one sheep at 26 weeks (decellularised pSFT).   
4 Weeks 12 Weeks 26 Weeks 
Decell pSFT* Ovine SFT* Decell pSFT Ovine SFT Decell pSFT* Ovine SFT 
Monocytes 0.5 ± 0.5 0.5 ± 0.5 0.3 ± 0.4 1.0 ± 0.0 0.3 ± 0.4 0.0 ± 0.0 
Polymorphonuclear cells 1.3 ± 1.3 0.8 ± 0.4 0.3 ± 0.4 1.0 ± 0.0 0.3 ± 0.4 0.0 ± 0.0 
Lymphocytes 0.8 ± 0.4 0.8 ± 0.4 0.5 ± 0.5 1.0 ± 0.0 1.0 ± 1.0 0.3 ± 0.0 
Synoviocytes 1.0 ± 0.0 1.3 ± 0.4 1.0 ± 0.0 1.5 ± 0.9 1.8 ± 0.8 1.3 ± 0.0 














1 slight  
Fig. 3. Images of sections of the intra-articular graft portion (left) stained with SHE showing cellular infiltration and of the graft within bone tunnels 
(right) stained with modified Paragon showing graft integration. Grafts showed evidence of cellular infiltration (CI), neovascularization (NV) at 4 weeks and 
ligamentisation (Lig) after 12 and 26 weeks. Within bone tunnels, evidence of cellular infiltration at the graft (G)- bone (B) junction could be seen at 4 weeks. By 12 
weeks, there was evidence of new bone formation (NB) and Sharpey’s fibres bridging the bone-tendon interface (SF). Evidence of ligament ossification (Oss) was 
observed at 26 weeks. Representative images shown, scale bars show 100 μm (except 4 weeks, bone tunnels, 1000 μm). 




Summary of the semi-quantitative histopathologic evaluation of the femoral bone tunnels. Qualitative and semi-quantitative evaluation of the different components was conducted as follows: Fibrin, necrosis, osteolysis, 
ligament calcification, ligament ossification, fibrous encapsulation and necrotic bone debris were graded from 0 (absent); 1 (slight); 2 (moderate); 3 (marked) and 4 (severe). Cellular components (PMNs, lymphocytes, 
plasma cells, macrophages and giant/osteoclastic cells) were graded from 0 (absent); 1 (slight or 1–5 cells per field of view at 400× magnification), 2 moderate (or 6–10 cells per FoV), 3 (marked or heavy cell infiltrate) and 
4 (severe or packed cells). Fibrosis was graded 0 (absent); 1 (narrow band); 2 (moderately thick band); 3 (thick band) and 4 (extensive band with signs of encapsulation). Fatty infiltrate and bone marrow was graded 
0 (absent); 1 (minimal amount associated with fibrosis); 2 (several layers of fat and fibrosis); 3 (elongated and broad accumulation of fat cells around implant site) and 4 (extensive fat completely surrounding the implant). 
Finally, neovascularization was graded 0 (absent); 1 (minimal capillary proliferation foci, 1–3 buds); 2 (groups of 4–7 capillaries with supporting fibroblastic structures); 3 (broad band of capillaries with supporting 































































































































































































































4 weeks Test (n = 4) Mean 0.0 1.3 2.3 1.8 2.0 1.0 0.5 1.0 1.0 0.0 1.0 0.5 0.5 0.0 0.8 0.0 1.0 2.0 1.0 1.0 0.0 1.0 
SD 0.0 0.4 0.4 0.4 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.5 0.5 0.0 0.4 0.0 0.0 0.7 0.0 0.0 0.0 0.0 
Control (n = 4) Mean 0.5 1.5 2.3 1.3 1.5 1.0 0.3 1.0 1.0 0.3 1.0 0.5 0.5 0.0 0.3 0.0 1.3 1.8 1.0 1.0 0.0 1.0 
SD 0.5 0.9 0.4 0.4 0.5 0.0 0.4 0.0 0.0 0.4 0.0 0.5 0.5 0.0 0.4 0.0 0.4 0.8 0.0 0.0 0.0 0.0 
12 weeks Test (n = 4) Mean 0.0 0.8 1.3 1.0 1.0 1.0 0.0 0.3 1.3 0.0 2.0 1.8 1.8 0.0 0.0 1.8 2.3 2.8 2.3 2.5 0.0 1.0 
SD 0.0 0.8 0.4 0.0 0.0 0.0 0.0 0.4 0.4 0.0 0.0 0.4 0.4 0.0 0.0 0.8 0.4 0.4 0.8 0.5 0.0 0.0 
Control (n = 4) Mean 0.3 0.5 1.0 0.3 1.0 1.0 0.0 0.0 1.0 0.0 2.0 1.8 1.8 0.0 0.0 1.3 2.5 2.5 1.8 1.8 0.0 1.0 
SD 0.4 0.5 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.4 0.0 0.0 0.4 0.5 0.5 0.4 0.4 0.0 0.0 
26 weeks Test (n = 4) Mean 0.3 1.3 1.8 1.0 1.3 1.0 0.0 1.0 1.3 0.5 1.3 1.8 1.8 0.0 0.0 2.0 2.3 3.0 2.3 2.0 0.5 1.0 
SD 0.4 0.4 0.4 0.0 0.4 0.0 0.0 0.7 0.4 0.9 0.4 0.4 0.4 0.0 0.0 1.2 0.8 0.7 0.8 0.7 0.9 0.0 
Control (n = 4) Mean 0.0 0.3 1.3 1.0 1.0 0.8 0.0 0.8 1.0 0.3 1.8 1.5 1.5 0.0 0.0 1.0 2.3 2.3 2.3 2.3 0.0 1.3 
SD 0.0 0.4 0.4 0.0 0.0 0.4 0.0 0.4 0.0 0.4 0.4 0.9 0.9 0.0 0.0 0.0 0.8 1.3 1.1 0.4 0.0 0.4  
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tissues. Rare MAC 387+ cells were found in the endotenon or synovial 
sheath (Figs. 5h and 7c). A significant proportion of the cells in the ovine 
ACL tissue sections were CD163+, located in the synovial sheath and 
endotenon regions with an irregular or rounded morphology with oc-
casional CD163+ cells elongated along the collagen fibrils (Figs. 5i and 
7d). A considerable proportion (circa 50%) of the cells present 
throughout the ovine ACL tissues expressed CTGF (Figs. 5j and 7e). 
Immunohistochemical analysis of sections of the intra-articular 
portion of explanted decellularised pSFT and oSFT revealed a similar 
pattern (Fig. 5). At 4 weeks large numbers of α-SMA + cells were present 
at the margins of the tissues between the collagen fibre bundles and 
along collagen fibres (Figs. 5a and 6f). The outer margins of the tissues 
contained numerous vascular structures, demarcated by α-SMA + cells 
(Fig. 6f). CD34+ cells were localised to the vascular structures (Figs. 5b 
and 6g). There were sparse CD271+ cells (Figs. 5c and 6h). There was 
mild to strong staining for tenascin-C (Fig 5d; Fig 6i) and collagen III (Fig 
5e; Fig 6j) along the collagen fibres in the areas of cellular population. 
Variable numbers of CD3+cells (Figs. 5f and 7f) and Ki-67+ cells 
(Figs. 5g and 7g) were present, largely in inflammatory foci in the 
margins all of the explanted tissues indicating an ongoing inflammatory 
response. There were high numbers of MAC 387+ cells (grade 3–4) in 
tissue sections from the three sheep (2 decellularised pSFT, 1 oSFT) 
which showed moderate/marked cellularity in synovial smears. These 
were most likely PMNs as judged by histology. Rare MAC 387+ cells 
were present in the remaining tissues (Figs. 5h and 7h). CD163+ cells 
were abundant in the cellular infiltrate at the margins of the tissues 
(Fig. 5i). Indeed, CD163+ cells appeared to be the “pioneer” cells at the 
interface between the pSFT tissue that was decellularised and the tissue 
that was populated by cells (Fig. 7i). A high proportion of the cells 
populating the tissues were positive for CTGF (Figs. 5j and 7j). 
After 12-weeks implantation, moderate to marked numbers of 
α-SMA + cells (Figs. 5a and 6k) were present in the central areas of the 
tissues. Abundant vascular structures were marked by CD34+ cells 
(Figs. 5b and 6l). Numbers of CD271+ cells increased, in a perivascular 
location (Figs. 5c and 6m). The mild to strong staining for tenascin-C 
(Fig 5d; Fig 6n) and collagen III (Fig 5e; Fig 6o) along the collagen fi-
bres was still present. CD3+ cells were present in a perivascular location 
throughout the tissues (Figs. 5f and 7k). Ki-67+ cells (Figs. 5g and 7l) 
and MAC 387+ cells (Figs. 5h and 7m) were rare. Moderate to marked 
numbers of CD163+ cells had penetrated the central areas of the tissues 
(Figs. 5i and 7n). A high proportion of the cells were positive for CTGF 
(Figs. 5j and 7o). 
At 26 weeks, marked numbers of the stromal cells were α-SMA+
(Figs. 5a, 6p and 5u). Overall there appeared to be a reduction in vas-
cularisation, indicated by a slight reduction in CD34+ cells (Figs. 5b, 6q 
and 6v) and CD271+ (Figs. 5c, 6r and 6w) cells compared to 12-weeks. 
At 26 weeks, the numbers α-SMA, CD34 and CD271 positive cells were 
similar to those in the native oACL tissue sections (Fig. 5a–c). Tenascin C 
staining had reduced to mild compared to 4 and 12 weeks (Fig 5d; Fig 6s; 
Fig 6x) whilst collagen III staining increased to moderate/strong (Fig 5e; 
Fig 6t; Fig 6y). The tissue sections all showed the presence of some CD3+
cells, however the numbers were reduced compared with the 4 and 12- 
week explants (Figs. 5f, 7p and 7u). Ki-67+ (Figs. 5g, 7q and 7v) and 
MAC 387+ cells (Figs. 5h, 7r and 7w) were absent/rare. Although still 
present in moderate numbers, numbers of CD163+ cells were reduced 
(Fig. 5i). The CD163+ cells were present in vascularised areas, in the 
outer sheaf and also as elongated cells along the collagen fibrils (Fig. 7s 
and x) in numbers similar to the native ovine ACL (Fig. 5i). A high 
proportion of the cells were positive for CTGF (Figs. 5j and 7t; Fig 7y), 
similar to native ovine ACL tissues. 
All tissue sections at 4, 12 and 26 weeks from the decellularised pSFT 
and oSFT were devoid of CD80+ and CD 19+ cells, only the occasional 
positive cell was identified in the inflammatory infiltrate of tissue from 
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3.7. Biomechanical function of oSFT and pSFT ACL replacement 
Biomechanical properties of reconstructed ovine ACLs (oSFT and 
pSFT at 26 weeks, pSFT(C)) are presented in Fig. 8, along with the 
properties of native ovine ACLs from contralateral knees. There were no 
significant differences between the properties of the pSFT and oSFT at 
26 weeks. There were no significant differences between the extension 
at failure for any group. All reconstructed ACLs showed a significantly 
lower (p < 0.05) linear stiffness compared to native ACL, with no further 
differences between groups. The load at failure for all reconstructed 
ACLs was significantly lower (p < 0.05) compared to the native ACL. In 
all native ACL, oSFT and pSFT at 26 weeks, failure mode was intra-
ligamentous, with the majority of failures occurring mid-ligament and 
the rest towards the femoral or tibial insertion but within the graft 
material (native ACL 4/6 mid-ligament, 2/6 femoral side; oSFT 5/6 mid- 
ligament, 1/6 tibial side; pSFT 4/6 mid-ligament, 2/6 femoral side). No 
failures were observed at the fixation points for the pSFT or oSFT grafts 
at 26 weeks. By comparison, for the pSFT implanted into cadaveric 
contralateral knees from the study animals (pSFT(C), all failures 
occurred due to failure at the interface and pull out of the graft from the 
tunnel (4/6 tibial insertion, 2/6 insertion). 
4. Discussion 
The primary purpose of this study was to evaluate the biological 
integration and mechanical performance of the decellularised pSFT in 
the sheep knee over a 6 month period. It was clearly demonstrated that 
the decellularised pSFT showed equivalent in vivo, biological and 
biomechanical performance compared to a cellular ovine SFT allograft 
control over a six month period. 
Decellularised pSFT for implantation were rigorously produced using 
a batch quality assurance approach. This demonstrated removal of 
cellular material and the majority of the DNA with mean total DNA 
content 14.9 ± 7.1 ng mg− 1, well below the suggested acceptable levels 
for biological scaffolds of 50 ng double stranded DNA per mg dry weight 
[14]. As reported previously [26] the use of low concentration SDS plus 
proteinase inhibitors enabled retention of the decellularised pSFT 
extracellular matrix structure. The failure load of the split decellularised 
pSFT extracellular matrix scaffolds (1238 ± 256 N) was comparable to 
the native ovine ACL from the literature (1200 ± 190 N [63]) and 
deemed suitable for reconstruction in this model. Although this is lower 
than the human ACL (2160 ± 157 N [64]), it is important to note that the 
cross sectional area of both the ovine ACL (20 ± 4 mm2 [63]) and split 
pSFT (32.3 ± 5.9 mm2) are lower than the human ACL (47 ± 13 mm2 
[65]). As the strength of a structure is dependent on cross-sectional area 
as well as the material properties, it is not possible to directly compare 
the results obtained in this study to the human ACL. 
Skeletally mature sheep were selected for the study because of the 
similarity of the knee to humans, allowing anatomic fixation. The main 
limitation of this model is that the ovine knee is smaller than the human 
and therefore requires smaller graft materials. Prior to commencing 
surgeries on living animals, several pilot studies were conducted in 
cadaveric sheep and sheep under non-recovery anaesthesia. The surgical 
technique, in terms of dimensions of the bone tunnels and the screws 
was investigated with input from the surgeon and research team. Due to 
the small size of the ovine stifle and high density of the cancellous bone, 
Fig. 4. DAPI and Masson’s trichrome stained sections of implanted grafts at each time point. Cellular infiltration was observed from 4 weeks, with evidence of 
vascularisation and further colonisation at 12 and 26 weeks for both pSFT and oSFT. Images are also provided for tissue from the native ovine ACL. Representative 
images shown, scale bars show 100 μm. 
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fixation procedures were modified slightly compared with human sur-
gical fixation. Graft diameter was reduced to a range of 6–7 mm as larger 
grafts (and therefore tunnels) would have resulted in damage to the 
menisci. The relative size of the interference screw compared with the 
bone tunnel was also decreased, enabling stable graft fixation despite 
the density of the graft material. A one-month pilot study in living an-
imals demonstrated that the final method of fixation was suitable. 
Sheep implanted with ovine SFT allografts were used as controls, 
since tendon allografts are used clinically and the performance of tendon 
allografts as ACL replacements in sheep has been widely reported [34, 
36,66,67]. Overall, both types of graft showed good in vivo performance 
with no major differences observed during the in-life phase or at 
macroscopic evaluation post euthanasia. 
Cytological analysis of the synovial fluids recovered from the 
implanted knees at termination indicated that, at 4 weeks, 2 of 4 fluids 
from knees implanted with pSFTs had moderate cellularity and 1 of 4 
fluids from knees implanted with an oSFT had marked cellularity. This 
was also the case for the synovial fluid from one of the knees implanted 
with a pSFT at 26 weeks which showed marked cellularity, however the 
presence of PMNs in these fluids indicated that the presence of infection 
could not be excluded. Importantly, for the knees implanted with pSFT, 
the levels of inflammation in the synovial fluids at 12 and 26 weeks was 
considered to be within normal limits and only adverse in the 26-week 
pSFT fluid which may have been infected. Histopathological evalua-
tion of the tendon tissue and bone tunnels, revealed an inflammatory 
reaction comprising lymphocytes, PMNs, macrophages and plasma cells 
to both the decellularised pSFT and oSFT allografts at 4 weeks which 
reduced by 26 weeks. Overall, while the pSFT elicited a slightly higher 
inflammatory reaction than the oSFT control, this did not impair graft 
performance in terms of biological integration and anchorage. Micro-
scopic evidence of acceptable local tissue effects were observed with 
both graft types, especially from 12 weeks of implantation with evidence 
of advanced cellular ingrowth and ligamentisation in the intra-articular 
graft and calcification, ossification and formation of Sharpey’s fibers at 
the graft/bone junctions. Inflammation is the initial response to tissue 
injury and hence the presence of inflammatory cells within the tissues at 
4 weeks was not unexpected. It is well documented that ACL recon-
struction with autografts and allografts in both humans [68,69] and 
sheep [66,70–72] involves an initial or inflammatory phase followed by 
tissue remodelling and maturation in the longer term. It is evident that 
an initial inflammatory response is necessary for subsequent integration 
and constructive remodelling of ACL grafts. 
In order to gain greater insight into the nature of the host response 
within the intra-articular grafts, antibodies to markers for lymphocytes 
(CD3 for T-cells; CD19 for B-cells) and macrophages were employed. 
Antibodies to MAC 387 detect migration inhibitory factor related pro-
tein (MRP14 [48]), expressed in mononuclear phagocytes and poly-
morphonuclear leukocytes [49]. MRP14 identifies recently infiltrating 
monocytes/macrophages [50]. Antibodies to CD163 bind to the high 
affinity scavenger receptor for the haemoglobin-haptoglobin complex 
and in humans, CD163 is considered a marker for M2 macrophages 
[40–42,73]. In sheep CD163 is expressed by cells in a similar localisation 
Fig. 5. Semi-quantitative analysis of the immunohistologically stained sections of implanted grafts and native ovine ACL at each time point. For cell 
markers the number of positive cells per high power field of view (40× objective; 400× magnification) were counted and scored: 0 for no cells; 1 (rare) for 1–5 cells; 2 
(moderate) for 6–10 cells; 3 (marked) for a heavy infiltrate and 4 (packed) for packed cells. For matrix proteins (tenascin C and collagen III) sections were scored 
0 (absent), 1 (slight) 2 (moderate), 3 (strong) and 4 (intense). Data are presented as mean (n = 4) ± SD. 
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as CD11b + macrophages in lymph nodes [44]. Here, CD163 was uti-
lised as a marker for tissue macrophages, putatively M2-type macro-
phages. Antibodies to CD80 bind to the co-stimulatory molecule B7.1 
which is expressed by M1 macrophages [43,45–47]. 
The lymphocytes present in the explanted decellularised pSFT and 
oSFT allograft tissues were identified as CD3+ T-cells. Semi-quantitative 
scoring for lymphocytes and CD3+ cells was similar. Proliferating cells 
(Ki-67+) were apparent within the inflammatory infiltrates at 4 weeks, 
perhaps indicating active proliferation of CD3+ cells, however prolif-
erating cells were rare at 12 and 26 weeks. There was a notable absence 
of any CD19+ cells or CD80+ cells in any of the tissues and MAC 387+
cells were only detected in significant numbers in the 4-week explants. 
There was no evidence to suggest an ongoing CD3+ T-cell mediated 
immune rejection response in the form ligament degradation, necrosis or 
activated CD80+ M1-type macrophages in the decellularised pSFT or 
oSFT grafts. It is possible that the grafts incited a Th2 –restricted 
response as has been reported for SIS in mice [74], although further 
investigation would be required to test this hypothesis. However, in 
support of this, the host response to the grafted tissues did appear to 
become dominated by CD163+ M2-macrophages. In the 4-week ex-
plants, CD163+ cells demarcated the decellularised and cellularised 
tissue regions appearing to be the “pioneer” cells infiltrating the matrix 
of the decellularised pSFT grafts. CD163+ cell numbers increased from 4 
to 12-weeks and then began to decline by 26-weeks to levels similar to 
those in the native ovine ACL tissues. Interestingly, M2-macrophages 
(ED-2+; rat equivalent of CD163) have also been identified to have an 
anabolic pro-regenerative role in a rat model of ACL reconstruction with 
a syngeneic tendon graft [75]. 
A high proportion of the stromal cells in the native ovine ACL tissues 
expressed α-SMA, indicating myofibroblasts [51]. A high proportion of 
the cells growing into the grafted tissues at 4 weeks expressed α-SMA 
and at 12 and 26-weeks the density of α-SMA + cells in the explanted 
decellularised pSFT and oSFT tissues was similar to native ovine ACL. 
Myofibroblasts play an important role in the maintenance of matrix 
homeostasis of ligamentous tissues and matrix contraction and restruc-
turing during healing [52], suggesting that these cells may have played a 
role in the ligamentisation observed from 12 weeks. Population of the 
implanted tissues by progenitor cells was investigated using CD271 
(nerve growth factor receptor) and CD34. CD271 is a marker for 
multipotential mesenchymal stromal cells [53]. CD34, conventionally 
considered to be a marker for haematopoietic progenitors is now rec-
ognised as a general marker for progenitor cells [56,57]. In the native 
ovine ACL and explanted tissues the vascular endothelium was strongly 
CD34+ and antibodies to CD34 also weakly stained stromal cells, 
potentially indicating progenitor cells. CD34+ was a useful marker for 
neo-vascularisation of the explanted tissues, which was evident at the 
tissue margins at 4 weeks, greatest at 12-weeks and reduced at 26 weeks. 
CD271+ cells were present in low numbers specifically in perivascular 
locations in the native ovine ACL, presumably identifying pericytes. CD 
271+ cells were identified in the same location in all explanted tissues, 
being most abundant at 12-weeks and reducing at 26-weeks. CTGF is a 
matricellular protein involved in the regulation of cellular activity and 
ECM production as well as fibrosis [54]. Moderate levels of CTGF were 
expressed by cells in the native ovine ACL, perhaps indicating that 
intrinsic CTGF expression is a feature of a dynamically loaded tissue, 
since cyclic strain has been shown to increase CTGF expression in ACL 
fibroblasts [55]. CTGF was expressed by cells populating the grafted 
tissues, at similar levels to those in native ovine ACL at 26-weeks. 
Cellular population of the grafted tissues was accompanied by matrix 
expression of tenascin-C. Tenascin-C is an extracellular matrix 
Fig. 6. Representative images of sections of the native ovine ACL and intra-articular graft portion stained with antibodies to α-SMA, CD 34, CD271, 
Tenascin C and collagen III. A-E Native ovine ACL; F-J decellularised pSFT explanted at 4 weeks; K–O; decellularised pSFT explanted at 12 weeks; P-T decellularised 
pSFT explanted at 26 weeks; U–Y ovine SFT (allograft control) explanted at 26 weeks. Images captured at 10× magnification unless otherwise stated. Scale bars show 
100 μm. 
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glycoprotein important in regulating cellular differentiation and pro-
liferation. In normal adult tendons, tenascin-C is expressed in regions 
transmitting high levels of mechanical force and during wound healing 
of tendon grafts [60,61]. Collagen Type III makes up circa 10% of the 
collagen in the ACL and its early expression in tendon tissues used for 
ACL reconstruction has been interpreted as a sign of ligamentisation 
[58]. Collagen III expression precedes collagen I expression during 
wound healing of ligaments [59]. Collagen III expression was associated 
with cellular repopulation in the explanted tissues, increasing over the 
26 week period, indicating matrix remodelling associated with the his-
tological evidence of ligamentisation. 
Overall, by 26 weeks the cellular population of the explanted tissues 
Fig. 7. Representative images of sections of the native ovine ACL and intra-articular graft portion stained with antibodies to CD3, Ki-67, MAC 387; CD163 and 
CTGF. A-E Native ovine ACL; F-J decellularised pSFT explanted at 4 weeks; K–O; decellularised pSFT explanted at 12 weeks; P-T decellularised pSFT explanted at 26 
weeks; U–Y ovine SFT (allograft control) explanted at 26 weeks. Images captured at 10× magnification unless otherwise stated. Scale bars show 100 μm. 
Fig. 8. Biomechanical properties of native and reconstructed ovine ACLs. Graphs show mean ± 95% confidence intervals. * denotes significant difference 
between groups (1-way ANOVA; p < 0.05, Tukey’s post hoc analysis). 
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was similar to native ACL with evidence that matrix remodelling was 
ongoing. At 4 and 12 weeks, recruitment of a constructive cell infiltrate 
appeared to be orchestrated by CD163+ M2 macrophages. Studies 
conducted by the Badylak group have characterized the macrophage 
response to a range of biological scaffolds in vivo and identified CD 163+
M2 macrophages as promoting constructive tissue remodelling [13,46, 
76]. This is the first study of a decellularised xenogeneic tissue for ACL 
replacement in a functional large animal model that has attempted to 
characterise the tissue remodelling process and supports the emerging 
paradigm for the role of M2 macrophages in constructive tissue 
remodelling of appropriately decellularised biological scaffolds. Inter-
estingly, the oSFT allograft appeared to undergo similar cellular events 
despite containing non-viable cellular components. The reasons for this 
are not entirely clear, however it is well documented that in the sheep 
model, ACL allografts are remodelled over time with no evidence of 
overt immune rejection. Thus, it might be postulated that the 
fresh-frozen ovine tendon allografts contain the necessary cues and 
cell-guidance micro-structure to modulate the host response, despite 
containing residual cell remnants. 
After 26 weeks implantation, the biomechanical properties of the 
oSFT allograft and decellularised pSFT grafts were comparable. An in-
crease in mechanical parameters compared with those implanted in 
contralateral cadaveric knees (pSFT(C)) indicated integration of the 
grafts over time. A change in failure mode was also observed, moving 
from failure at the graft interface in the pSFT(C) grafts to ligamentous 
failure by week 26. Importantly, no grafts tested after 26 weeks failed at 
the graft-tunnel interface. This suggests that the remodelling observed in 
histological analysis was accompanied by improvements in graft sta-
bility. Although not the primary purpose of this study, grafts at 26 weeks 
were also compared with the biomechanical properties of the cadaveric 
contralateral ACLs. Neither type of graft had restored mechanical 
function to the level of the native ovine ACL, at 26 weeks, the failure 
load of the decellularised pSFT was 45% and oSFT allograft was 52% of 
the native ovine ACL (1114 ± 225 N). The linear stiffness of the decel-
lularised pSFT was 46% and oSFT allograft was 43% of the native ovine 
ACL (162 ± 52 N mm− 1). The data compared favourably to other studies 
reported in the literature at similar time points [27,29,33,34]. For 
example, Hunt et al. [34] reported a failure load of 313.8 N (20% of 
native ovine ACL) and a linear stiffness of 58.6 N.mm-1 (40% of native 
ovine ACL) for superficial flexor digitorum tendon allograft in sheep at 
24 weeks. Mayr et al. [36] recorded higher values for linear stiffness 
(146.0 ± 69.3 N. mm− 1) and failure load (807.9 ± 344.7 N) for flexor 
digitorum superficialis tendon allografts in sheep at 24 weeks, but this 
was 56% and 46% of the values recorded for linear stiffness and failure 
load of the native ovine ACL in their study. It is not clear at what time 
point the biomechanical properties of the native ACL are achieved, if 
ever, by an allograft in sheep [36]. Since the current study was limited to 
26-weeks, it is not known whether there would be any difference in the 
longer term biomechanical performance of the decellularised pSFT 
compared to the oSFT allograft. 
This study had several limitations. Since the study was conducted in 
sheep, the data cannot be directly translated to humans. The study was 
limited to 26 weeks, and although the time course for mechanical sta-
bility of ACL grafts in sheep is unclear, it is probable that this can take 
over a year [34,36]. The number of replicates analysed histologically 
and immunohistochemically at each time point was small (n = 4) and 
hence the study lacked statistical power. For this reason, quantitative 
histomorphometric analysis was not conducted. Longer term studies 
with increased numbers of animal replicates were not justified when this 
study was designed since, at the time, there were no published studies of 
functional ACL replacement in a large animal model with a decellu-
larised xenogeneic biological scaffold and the outcome was uncertain. 
5. Conclusions 
This study provides evidence for the initial integration and 
functional performance of an “off the shelf” decellularised xenograft 
scaffolds as an alternative to current allograft replacement of the ACL. 
The study also provides new insight into the host response to tendon 
allografts and functional biological scaffolds used for ACL reconstruc-
tion. The study supports the emerging paradigm for a role of M2 mac-
rophages in constructive tissue remodelling of appropriately 
decellularised biological scaffolds. 
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